Merck & Co. on Thursday won the first U.S. approval for a new kind of cancer drug with big advantages over chemotherapy and other older cancer treatments.
(HealthDay)—A new class of sleep medications appears to help people fall asleep without causing grogginess the next day, researchers say.
A vaccine against cervical cancer, being developed by Inovio Pharmaceuticals Inc. of Blue Bell, Pa., produced positive results in a small sample of 18 women.
For Alzheimer's patients and their families, desperate for an effective treatment for the epidemic disease, there's hope from new studies starting up and insights from recent ones that didn't quite pan out.
In a new study published in Nature Genetics researchers say that women who possess a fault in a gene named RAD51D have a greater risk of developing ovarian cancer than women who do not have this fault and tests are expect ...
Merck & Co. Inc. has won federal approval for a new type of sleeping pill designed to help people with insomnia stay asleep.
(HealthDay)—Packaging defects have prompted a recall of a combination cholesterol drug called Liptruzet, produced by Merck & Co., temporarily affecting the entire U.S. stock.
A combination drug containing niacin failed to lower the risk of heart attacks or strokes and even proved harmful for some with vascular disease, a study released Saturday reported.
(HealthDay)—The cervical cancer vaccine has turned into one of the biggest success stories in the field.
(HealthDay)—There may be good news coming in the form of a pill for the millions of Americans who suffer from ragweed allergy.
Merck & Co. says it's won its first approval for its new immunotherapy tablet for grass allergies, from regulators in Canada.
Northwestern Medicine, Walgreens, Alliance of Chicago community health centers and Merck are collaborating on a study with a deceptively simple goal: provide clear instructions on prescription medicine labels so patients ...
Merck & Co. could get an impressive six new prescription medicines approved in the U.S. this year and will soon apply for regulatory approval of two others, company executives said Tuesday during a briefing on Merck's business.
(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Intern ...
German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer.